Trial Profile
A Randomised, Double-blind, Placebo-controlled Trial in Healthy Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 2.5 mg to 160 mg of BI 163538 XX
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2013
Price :
$35
*
At a glance
- Drugs BI 163538 XX (Primary)
- Indications Obesity
- Focus Adverse reactions
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 May 2012 New trial record